Compare · IMNN vs NVO
IMNN vs NVO
Side-by-side comparison of Imunon Inc. (IMNN) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both IMNN and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $215.46B, about 23130.9x IMNN ($9.3M).
- IMNN has been more active in the news (17 items in the past 4 weeks vs 9 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 0 for IMNN).
- Company
- Imunon Inc.
- Novo Nordisk A/S
- Price
- -
- -
- Market cap
- $9.3M
- $215.46B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 17
- 9
- Recent ratings
- 0
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest IMNN
- President and CEO Lindborg Stacy was granted 6,615 shares, increasing direct ownership by 8% to 93,254 units (SEC Form 4)
- Chief Medical Officer Faller Douglas Vincent was granted 3,516 shares, increasing direct ownership by 12% to 33,451 units (SEC Form 4)
- Executive Chairman of Board Tardugno Michael H was granted 7,147 shares, increasing direct ownership by 9% to 82,504 units (SEC Form 4)
- General Counsel and Corp Sec Eylward Susan was granted 2,449 shares and sold $3,993 worth of shares (2,449 units at $1.63) (SEC Form 4)
- Imunon Inc. filed SEC Form 8-K: Leadership Update
- SEC Form 10-Q filed by Imunon Inc.
- Imunon Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- IMUNON Reports Second Quarter 2026 Financial Results and Provides Business Update
- Director Pellizzari Christine A was granted 6,934 shares, increasing direct ownership by 85% to 15,076 units (SEC Form 4)
- Director Dentzer James E was granted 6,934 shares, increasing direct ownership by 46% to 21,897 units (SEC Form 4)
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- A New Category Is Forming in Medical Aesthetics. Independent Research Has Started Sizing It.
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Berenberg
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S